Kriya Announces Thirteen Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2025 – Kriya’s platform includes fully integrated best-in-class manufacturing and research capabilities to support parallel advancement of a broad pipeline of gene therapies –
Kriya is a biopharmaceutical company developing gene therapy to address common diseases that impact millions of people worldwide. Learn more.
Kriya is developing a portfolio of one-time gene therapies in ophthalmology, metabolic disease and neurology.
Since its founding in October 2019, Kriya has raised over $600 million in committed capital—and with this financing, Kriya’s cash runway is anticipated to run into late 2026. Kriya is developing a portfolio of transformational gene therapies focused on three main therapeutic areas: ophthalmology, neurology and metabolic disease.
Kriya Announces $150 Million Addition to its Series C, Bringing Total ...
Careers Kriya is Changing the Future of Gene Therapy We have an ambitious set of goals, but our confidence – and our inspiration – stems from our people. From California to North Carolina, our teammates bring creativity, leadership, and a spirit of collaboration to their work every day.
Kriya is developing KRIYA 839, a potential one-time gene therapy for type 1 diabetes expressing insulin and glucokinase, designed to be delivered intramuscularly with the objective of driving durable glycemic control and reducing or eliminating the need for exogenous insulin. Kriya is initially evaluating its gene therapy in type 1 diabetes.
Kriya’s team of gene therapy pioneers and biopharma veterans is building a pipeline to address common diseases.